A Review on FDA Approval of Lymphoma Drug Ukoniq (Umbralisib) And Its Withdrwal Due to Safety Concerns . Journal of Pharmaceutical Negative Results. 2022;13(4):1465-1474. doi:10.47750/pnr.2022.13.04.206